Title : Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.

Pub. Date : 2015 May

PMID : 24961662






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AIM: The efficacy and safety of simeprevir in combination with peginterferon-alpha-2b and ribavirin (PEG IFN-alpha-2b/RBV) were investigated in patients infected with hepatitis C virus (HCV) genotype 1 who were treatment-naive or had previously received interferon (IFN)-based therapy. Simeprevir interferon alpha 1 Homo sapiens
2 CONCLUSION: Simeprevir combined with PEG IFN-alpha-2b/RBV was effective in patients infected with HCV genotype 1, both for initial treatment of naive patients and for retreatment of patients in whom previous IFN-based therapy had failed. Simeprevir interferon alpha 1 Homo sapiens